News & Updates

The selective oral PARP1/2 inhibitor pamiparib is well tolerated and demonstrates favourable antitumour activity with durable responses in the treatment of patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer harbouring the germline BRCA mutation, according to the results of a phase II trial.

Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.

Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.

Pretreatment with the cyclin-dependent kinase 4/6 inhibitor trilaciclib appears to enhance the antitumour efficacy of gemcitabine plus carboplatin, with significant survival gains for patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a phase II trial.

Intravenous thrombolysis with tenecteplase up to 24 hours after a stroke appears to re-establish blood flow in patients with large-vessel acute ischaemic stroke selected with advanced imaging, the phase IIa CHABLIS-T study has shown.

The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.

Use of moderate- to high-intensity statins (MHIS) after myocardial perfusion imaging (MPI) leads to significantly fewer major adverse cardiovascular events (MACE) and is an independent negative predictor for 24-months MACE among patients with normal MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.